Biohit Oyj stock analysis
Biohit Oyj (0DRP) Share Price & Analysis
0DRP Stock Chart & Stats
- Day’s Range
- EUR 2.16 - EUR 2.16
- 52-Week Range
- EUR 2.08 - EUR 3.77
- Previous Close
- EUR 2.17
- Volume
- N/A
- Average Volume (3M)
- 525
- Market Cap
- EUR 32.08M
- Enterprise Value
- EUR 41.56M
- Total Cash (Recent Filing)
- EUR 6.70M
- Total Debt (Recent Filing)
- EUR 600.00K
- Price to Earnings (P/E)
- 10.3
- Beta
- 1.13
- Next Earnings
- Feb 17, 2027 (Est.)
- EPS Estimate
- 0.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
0DRP FAQ
What was Biohit Oyj’s price range in the past 12 months?
What is Biohit Oyj’s market cap?
When is Biohit Oyj’s upcoming earnings report date?
How were Biohit Oyj’s earnings last quarter?
Is Biohit Oyj overvalued?
Does Biohit Oyj pay dividends?
What is Biohit Oyj’s EPS estimate?
How many shares outstanding does Biohit Oyj have?
What happened to Biohit Oyj’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Biohit Oyj?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Biohit Oyj
Helsinki-based Biohit Oyj is a biotechnology company that specializes in developing and distributing diagnostic tests and analytical systems worldwide for healthcare providers and research institutions. Their comprehensive portfolio of diagnostic solutions includes the GastroPanel test, designed for evaluating stomach conditions and associated risks, alongside tests for active vitamin B12 levels (Biohit Active B12) and vitamin D status (Biohit Total). They also offer the Biohit Calprotectin test, various methods for detecting Helicobacter pylori infection from biopsy samples, the ColonView Quick Test for identifying fecal occult blood, rapid tests for Lactose Intolerance and Celiac Disease, and the GA-map Dysbiosis test for detailed gut microbiota DNA analysis. Beyond diagnostics, Biohit manufactures products that bind carcinogenic acetaldehyde into harmless compounds, such as Acetium capsules for individuals with low stomach acidity, and Acetium lozenges, which neutralize acetaldehyde in smokers' saliva. The company also supplies monoclonal antibodies crucial for research in cellular pathology, neurobiology, oncology, and human gastric biomarkers. Additionally, their offerings extend to laboratory instrumentation, including microplate readers, strip washers, quick test readers, and the ThunderBolt automated immunoassay analyzer, complemented by comprehensive service laboratory provisions. Biohit Oyj was founded in 1988.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jussi Hahtela
- Employees
- 47
- Website
- www.biohithealthcare.com
- Address
- Laippatie 1, Helsinki, UU, 00880, FI
Biohit Oyj (0DRP) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 6 | 10 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 4 | 0 | 8 |

